Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2017 – Multiple Myeloma
ASCO 2017 – Multiple Myeloma
Daratumumab in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): An Open-Label Phase 1b Study
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.
Read Article
Open-Label, Single-Arm Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone, and Elotuzumab in Newly Diagnosed MM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).
Read Article
A Phase 1b Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.
Read Article
Phase 1/2 Dose Expansion of a Trial Investigating Bendamustine and Pomalidomide with Dexamethasone in Patients with RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Doxorubicin Hydrochloride, Lenalidomide, and Dexamethasone versus Bortezomib, Lenalidomide, and Dexamethasone Prior to Scheduled Stem-Cell Transplant in Newly Diagnosed Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The DSMM XIV study highlights the efficacy of bortezomib versus doxorubicin in combination with lenalidomide and dexamethasone prior to stem-cell transplant in patients with newly diagnosed multiple myeloma.
Read Article
Lenalidomide Induction and Maintenance Therapy for Transplant-Eligible Myeloma Patients: Results of the Myeloma XI Study
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
The Myeloma XI Study analyzed lenalidomide induction and maintenance therapy in transplant-eligible patients with myeloma.
Read Article
Impact of t(11;14) on Outcomes in African American and Non–African American Patients with NDMM: Connect MM Registry
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation.
Read Article
Pembrolizumab plus Lenalidomide and Low-Dose Dexamethasone for RRMM: Efficacy and Biomarker Analyses
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Results from the KEYNOTE-023 trial show that the combination of pembrolizumab plus lenalidomide and low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T-Cell Therapy for RRMM: Updated Results
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Chimeric antigen receptor (CAR) T-cell therapy with bb2121 shows a promising new treatment paradigm in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Pomalidomide + Low-Dose Dexamethasone after Lenalidomide-Based Second-Line Treatment in Patients with RRMM: Analysis of Progression-Free Survival by Level of Disease Control
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
Pomalidomide plus low-dose dexamethasone used as third-line therapy improves survival outcomes in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma